Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei

Cellular and Molecular Neurobiology

Volumn 22, Issue 5-6, 2002, Pages 699-709

  Furio, Analía M ^b   Cutrera, Rodolfo A ^b   Thea, Victor Castillo ^b   Lloret, Santiago Pérez ^b   Riccio, Patricia ^b   Caccuri, Roberto L ^b   Brusco, Luis I ^b   Cardinali, Daniel P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE

Author keywords

Alzheimer's disease; Beta amyloid peptide; Circadian rhythms; Melatonin suprachiasmatic nucleus; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; ANTIOXIDANT; DRINKING WATER; MELATONIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CHRONOBIOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; HORMONE ACTION; HYPOTHALAMUS; INFORMATION PROCESSING; LIGHT DARK CYCLE; LOCOMOTION; MALE; MICROINJECTION; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; RUNNING; SUPRACHIASMATIC NUCLEUS; SYRIAN HAMSTER;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; CRICETINAE; DRUG INTERACTIONS; MALE; MELATONIN; MESOCRICETUS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; SUPRACHIASMATIC NUCLEUS; TREATMENT OUTCOME;

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

EID: 0036973151     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021805023906     Document Type: Article

References (48)

1. Brusco, L. I., Marquez, M., and Cardinali, D. P. (1998a). Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Lett. 19:111-115.
2. Brusco, L. I., Marquez, M., and Cardinali, D. P. (1998b). Monozygotic twins with Alzheimer's disease treated with melatonin: Case report. J. Pineal Res. 25:260-263.
3. Cardinali, D. P., Brusco, L. I., Liberczuk, C., and Furio, A. M. (2002a). The use of melatonin in Alzheimer's disease. Neuroendocrinol. Lett. 23(Suppl. 1):26-29.
4. Cardinali, D. P., Gvozdenovich, E., Kaplan, M. R., Fainstein, I., Shifis, H. A., Pérez Lloret, S., Albornoz, L. E., and Negri, A. (2002b). A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol. Lett. 23:55-60.
5. Cardinali, D. P., and Pevet, P. Basic aspects of melatonin action. (1998). Sleep Med. Rev. 2:175-190.
6. Cohen-Mansfield, J., Garfinkel, D., and Lipson, S. (2000). Melatonin for treatment of sundowning in elderly persons with dementia. Arch. Gerontol. Geriatr. 31:65-76.
7. Dori, D., Casale, G., Solerte, S. B., Fioravanti, M., Migliorati, G., Cuzzoni, G., and Ferrari, E. (1994). Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21:121-126.
8. Fainstein, I., Bonetto, A., Brusco, L. I., and Cardinali, D. P. (1997). Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr. Ther. Res. 58:990-1000.
9. Flood, J. F., Morley, J. E., and Roberts, E. (1991). An amnestic effect in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 88:3363-3366.
10. Girotti, L., Lago, M., Yanovsky, O., Carbajales, J., Elizari, M., Brusco, L. I., and Cardinali, D. P. (2000). Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J. Pineal Res. 29:138-142.
11. Giubilei, F., Patacchioli, F. R., Antonini, G., Sepe, M. M., Tisei, P., Bastianello, S., Monnazzi, P., and Angelucci, L. (2001). Altered circadian cortisol secretion in Alzheimer's disease: Clinical and neuroradiological aspects. J. Neurosci. Res. 66:262-265.
12. Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., and Ostaszewski, B. L. (1992). Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325.
13. Harper, D. G., Stopa, E. G., McKee, A. C., Satlin, A., Harlan, P. C., Goldstein, R., and Volicer, L. (2001). Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch. Gen. Psychiatry 58:353-360.
14. Hoogendijk, W. J., van Someren, E. J., Mirmiran, M., Hofman, M. A., Lucassen, P. J., Zhou, J. N., and Swaab, D. E. (1996). Circadian rhythm-related behavioral disturbances and structural hypothalamic changes in Alzheimer's disease. Int. Psychogeriatr. 8:245-252.
15. Iguchi, H., Kato, K. I., and Ibayashi, H. (1982). Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J. Clin. Endocrinol. Metab. 55:27-29.
16. Jean-Louis, G., Zizi, F., von Gizycki, H., and Taub, H. (1998). Effects of melatonin in two individuals with Alzheimer's disease. Percept. Mot. Skills 87:331-339.
17. Kontush, A., Mann, U., Ant, S., Ujeyl, A., Lürs, C., Möller-Thomsen, T., and Beisiegel, U. (2001). Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Rad. Biol. Med. 31:345-354.
18. Liu, R. Y., Zhou, J. N., van Heerikhuize, J., Hofman, M. A., and Swaab, D. F. (1999). Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J. Clin. Endocrinol. Metab. 84:323-327.
19. Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W. (1993). Apoptosis is induced by β-amyloid in culture central nervous system neurons. Proc. Natl. Acad. Sci. U.S.A. 90:7951-7955.
20. Luboshitzky, R., Shen-Orr, Z., Tzischichinsky, O., Maldonado, M., Herer, P., and Lavie, P. (2001). Actigraphic sleep-wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer's disease. Chronobiol. Int. 18:513-524.
21. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992). β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:376-389.
22. McCurry, S. M., Reynolds, C. F., Ancoli-Israel, S., Teri, L., and Vitiello, M. V. (2000). Treatment of sleep disturbance in Alzheimer's disease. Sleep Med. Rev. 4:603-628.
23. Mesulam, M. M. (1999). Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24:521-529.
24. Miranda, S., Opaza, C., Larrondo, L. F., Muñoz, F. J., Ruiz, F., Leighton, F., and Inestrosa, N. C. (2000). The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog. Neurobiol. 62:633-648.
25. Mishima, K., Okawa, M., Hozumi, S., and Hishikawa, Y. (2000). Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol. Int. 17:419-432.
26. Mishima, K., Okawa, M., Shimizu, T., and Hishikawa, Y. (2001). Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J. Clin. Endocrinol. Metab. 86:129-134.
27. Monti, J. M., and Cardinali, D. P. (2000). A critical assessment of melatonin effect on sleep in humans. Biol. Signals Recept. 9:328-339.
28. Nitta, A., Itoh, A., Hasegawa, T., and Naveshima, T. (1994). β-amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170:63-66.
29. Pappolla, M. A., Chyan, Y., Poeggeler, B., Frangione, B., Wilson, G., Ghiso, J., and Reiter, R. J. (2000). An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for Alzheimer's disease. J. Neural Transm. 107:203-231.
30. Pappolla, M. A., Sos, M., Omar, R. A., Bick, R. J., Hickson-Bick, D. L., Reiter, R. J., Efthimiopoulos, S., and Robakis, N. K. (1997). Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. 17:1683-1690.
31. Reiter, R. J., Acuña-Castroviejo, D., Tan, D. X., and Burkhardt, S. (2001). Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. N.Y. Acad. Sci. 939:200-215.
32. Reiter, R. J., Cabrera, J., Sainz, R. M., Mayo, J. C., Manchester, L. C., and Tan, D. X. (1999). Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann. N.Y. Acad. Sci. 890:471-485.
33. Reiter, R. J., Tan, D. X., Acuña-Castroviejo, D., Burkhardt, S., and Karbownik, M. (2000). Melatonin: Mechanisms and actions as an antioxidant. Curr. Top. Biophys. 24:171-183.
34. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., and Corman, C. W. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1216-1222.
35. Savaskan, E., Olivieri, G., Meier, F., Brydon, L., Jockers, R., Ravid, R., and Wirz-Justice, A. (2002). Increased melatonin la-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 32:59-62.
36. Sayre, L. M., Smith, M. A., and Perry, G. (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8:721-738.
37. Selkoe, D. J. (1991). The molecular pathology of Alzheimer's disease. Nature 6:487-498.
38. Shearman, M. S., Ragan, C. I., and Iversen, L. L. (1994). Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U.S.A. 91:1470-1474.
39. Shen, Y. X., Xu, S. Y., Wei, W., Sun, X. X., Liu, L. H., Yang, J., and Dong, C. (2002). The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J. Pineal Res. 32:85-89.
40. Siegrist, C., Benedetti, C., Orlando, A., Beltran, J. M., Tuchscherr, L., Noseda, C. M., Brusco, L. I., and Cardinali, D. P. (2001). Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J. Pineal Res. 30:34-42.
41. Skinner, D. C., and Malpaux, B. (1999). High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 140:4399-4405.
42. Smith, M. A., Hirai, K., Hsiao, K., Pappolla, M. A., Harris, P. L., Siedlak, S. L., Tabaton, M., and Perry, G. (1998). Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:2212-2215.
43. Smith, M. A., Rottakamp, C. A., Nunomura, A., Rama, A. K., and Perry, G. (2000). Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502:139-144.
44. Swabb, D. F., Fliers, E., and Partiman, T. S. (1985). The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342:37-44.
45. Taylor, J. L., Friedman, L., Sheikh, J., and Yesavage, J. A. Assessment and management of "sundowning" phenomena. (1997). Semin. Clin. Neuropsychiatry 2:113-122.
46. van Someren, E. J. W. (2000). Circadian rhythms and sleep in human aging. Chronobiol. Int. 17:233-243.
47. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999). Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741.
48. 2+ channel blockers attenuate β-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. 62:372-375.